So, the FDA has sent a not-so-friendly reminder to Medline Inc. (MDLN) about the importance of quality control. In a warning letter dated March 25, regulators laid out a series of manufacturing and quality system failures at Medline's New York facility, focusing on its angiographic control syringes and related kits. The bottom line from the inspection last December: these devices are considered "adulterated" under federal law because they didn't meet good manufacturing practice standards. That's regulatory-speak for "this is a problem."

The core issue, according to the FDA, is that Medline's system for fixing problems—its corrective and preventive action, or CAPA, process—basically broke down. Here's the concerning part: the company had received 221 complaints and filed 177 medical device reports all tied to syringe disconnections. In response, Medline did things like scrap some inventory and clean equipment more often. But the FDA says those steps weren't enough given the severity of the risk. It's like putting a small bandage on a significant wound and calling it a day.

What really seemed to bother the regulators were the inconsistencies. Internally, Medline's own analyses flagged severe risks, including the potential for air embolism—a serious and sometimes fatal complication. Yet, the company's overall risk classification for the issue was "low." Furthermore, even after Medline implemented its corrective actions, complaint trends stayed above the company's own established thresholds. Despite that, Medline didn't escalate or reopen its investigations as it should have, which is a key part of a functioning quality system.

Medline has acknowledged the shortcomings. It closed the initial CAPA and started new investigations alongside a plan to remove affected products from the market. The company even submitted a formal report to the FDA in March 2026 detailing the removal. However, the FDA isn't fully satisfied. The warning letter points to gaps in the scope and timeline of these actions. Things like unclear investigation deadlines and inconsistencies in the manufacturing data related to complaint rates mean the response, in the FDA's view, still isn't airtight.

The problems don't stop with the syringes. The FDA also called out Medline for failing to keep its cleanroom, well, clean. Inspectors found visible particulate matter on manufacturing equipment. Over a two-year period, the company logged more than 100 complaints related to foreign material contamination. While Medline says it took corrective cleaning measures and updated its procedures, the FDA argues the company didn't do enough to assess the impact on products that were already out in the market and potentially in use. There were also issues with design verification. The FDA found that Medline's documentation supporting testing decisions for device components was insufficient, raising questions about whether all the affected products actually met the required standards.

So, what's next? The FDA has warned that if Medline doesn't properly address all these issues, it could face enforcement actions, including fines or even having its products seized. The company has been directed to submit a detailed remediation plan within 15 business days. All its corrective actions need to align with the updated Quality Management System Regulation requirements that just took effect in February 2026. This isn't Medline's only recent brush with regulators, either. Back in February, the company itself identified electrical safety risks with its Medline Basic Homecare Beds that may lead to fire.

Despite the regulatory headwinds, Medline shares were up 2.93% at $45.64 at the time of publication on Thursday.